The mesenchymal stem cell profile in psoriasis

British Journal of Dermatology

Volumn 165, Issue 3, 2011, Pages 585-592

  Orciani, M ^a   Campanati, A ^a   Salvolini, E ^a   Lucarini, G ^a   Di Benedetto, G ^b   Offidani, A ^a   Di Primio, R ^a  

^a Department of Molecular Pathology and Innovative Therapies ^*  (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; NITRIC OXIDE; OXYGEN RADICAL; PEROXYNITRITE; VASCULOTROPIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATOPIC DERMATITIS; ATOPY; CELL ISOLATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MEDIATOR RELEASE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PUNCH BIOPSY; SKIN DEFECT;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; CELLS, CULTURED; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; PSORIASIS; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052273987     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10438.x     Document Type: Article

References (31)

1. Boehncke WH, Dressel D, Zollner TM, et al. Pulling the trigger on psoriasis. Nature 1996; 379: 777.
2. Krueger JG, Bowcock A,. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64: Sii30-6.
3. Christophers E,. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20. (Pubitemid 34204344)
4. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-11. (Pubitemid 351543220)
5. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing 'T22' T-cells account for up-regulated IL-22 in atopic dermatitis (AD), despite reduced IL-17-producing TH17 T-cells. J Allergy Clin Immunol 2009; 123: 1244-52.
6. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
7. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007; 119: 1210-17. (Pubitemid 46654193)
8. Ong PY, Leung DY,. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006; 6: 384-9. (Pubitemid 44340170)
9. Henno A, Blacher S, Lambert C, et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br J Dermatol 2009; 160: 581-90.
10. Sirsjö A, Karlsson M, Gidlöf A, et al. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol 1996; 134: 643-8. (Pubitemid 26120732)
11. Canavese M, Altruda F, Ruzicka T, et al. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermatol Sci 2010; 58: 171-6.
12. Okayama Y,. Oxidative stress in allergic and inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 517-19. (Pubitemid 41052420)
13. Orciani M, Gorbi S, Benedetti M, et al. Oxidative stress defense in human-skin-derived mesenchymal stem cells versus human keratinocytes: different mechanisms of protection and cell selection. Free Radic Biol Med 2010; 49: 830-8.
14. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-17. (Pubitemid 44269669)
15. Minardi D, Lucarini G, Filosa A, et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol 2008; 21: 447-55. (Pubitemid 351988410)
16. McNaughton L, Puttagunta L, Martinez-Cuesta MA, et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci USA 2002; 99: 17161-6. (Pubitemid 36034115)
17. Salvolini E, Lucarini G, Zizzi A, et al. Human skin-derived mesenchymal stem cells as a source of VEGF and nitric oxide. Arch Dermatol Res 2010; 302: 367-74.
18. Bradford M,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
19. Gorbi S, Regoli F,. Total oxyradical scavenging capacity as an index of susceptibility to oxidative stress in marine organisms. Comments Toxicol 2003; 9: 303-22. (Pubitemid 38867839)
20. Regoli F, Winston GW,. Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Toxicol Appl Pharmacol 1999; 56: 96-105. (Pubitemid 29196572)
21. Micali G, Lacarrubba F, Musumeci ML, et al. Cutaneous vascular patterns in psoriasis. Int J Dermatol 2010; 49: 249-56.
22. van de Kerkhof PCM, van Rennes H, de Grood R,. Metabolic changes at the margin of the spreading psoriatic lesion. Br J Dermatol 1983; 108: 647-52. (Pubitemid 13100183)
23. Campanati A, Goteri G, Simonetti O, et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2009; 22: 371-7.
24. Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2011; 18: 3262-9.
25. Rosenkranz-Weiss P, Sessa WC, Milstein S, et al. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells: elevation in tetrahydrobiopterin levels enhances endothelial nitric oxide synthase specific activity. J Clin Invest 1994; 93: 2236-43.
26. Cooper KD,. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994; 102: 128-37. (Pubitemid 24039577)
27. Liew FY, Li Y, Severn A, et al. A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol 1991; 21: 2489-94.
28. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-62. (Pubitemid 43049565)
29. Hashemi M, Mehrabifar H, Daliri M, et al. Adenosine deaminase activity, trypsin inhibitory capacity and total antioxidant capacity in psoriasis. J Eur Acad Dermatol Venereol 2010; 24: 29-34.
30. Briganti S, Picardo M,. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 2003; 17: 663-9. (Pubitemid 37428088)
31. Pastore S, Korkina L,. Redox imbalance in T cell-mediated skin diseases. Mediators Inflamm 2010; 2010:861949.